“And it will still be in that zero to $15 billion range is our sweet spot, but obviously, open to looking at deals.”

In context

“L as a growth driver because we always had an expectation that eventually, it would start to plateau as we got through all of the cohorts. And really, we're back to just the birth cohort. So, as we look forward, our expectation for what the post-LOE period looks like is frankly unchanged from what I previously communicated. That said, as we've also communicated, while I feel increasingly confident about that period, we have always said we do believe we need to do more to continue to augment the pipeline we've built. And so, we will continue to do -- to drive business development and we're looking at business development in a full range, always with science being the leading question. But if we can see value and a tie in to our strategy where science intersects, we will be willing to move. And it will still be in that zero to $15 billion range is our sweet spot, but obviously, open to looking at deals. And as we've also said, we're open to commercialized assets as well, if they fit the overall profile I laid out of science and value. Operator: Thank you. Our next question comes from Luisa Hector with Berenberg. Your line is open. You may ask your question. Luisa Hector: Perhaps on the oral PCSK9, could you just add a bit more color around what you're targeting for cholesterol lower, whether we might need to see all three trials in-house before you issue a press release? And I think you mentioned before potential combinations. Obviously, you have now optionality on the oral GLP. So just perhaps some color around where you could go with further development. Dr. Dean Li: I'll take that. Thank you very much for the question. This is Dean. Yes, we have three Phase 3s that are ongoing that sh”